Laparoscopic sentinel lymph node procedure using a combination of patent blue and radioisotope in women with cervical carcinoma

✍ Scribed by Emmanuel Barranger; Dany Grahek; Annie Cortez; Jean Noel Talbot; Serge Uzan; Emile Darai

• Book ID: 102108932
• Publisher: John Wiley and Sons
• Year: 2003
• Tongue: English
• Weight: 187 KB
• Volume: 97
• Category: Article
• ISSN: 0008-543X
• DOI: 10.1002/cncr.11423

✦ Synopsis

Abstract

BACKGROUND

The authors evaluated the feasibility of a laparoscopic sentinel lymph node (SN) procedure with combined radioisotopic and patent blue labeling in patients with cervical carcinoma.

METHODS

Thirteen women (median age, 52.5 years) with cervical carcinoma (Stage Ia2 in 1 patient, Stage Ib1 in 10 patients, Stage Ib2 in 1 patient, and Stage IIa in 1 patient) underwent a laparoscopic SN procedure using an endoscopic γ probe after both radioactive isotope and patent blue injections. After the procedure, all patients underwent complete laparoscopic pelvic lymphadenectomy and either laparoscopic radical hysterectomy (eight patients) or the Schauta–Amreich operation (five patients).

RESULTS

SNs (mean, 1.7 SNs per patient; range, 1–3 SNs per patient) were identified in 12 of 13 patients. A median of 10.5 pelvic lymph nodes per patient (range, 4–17 pelvic lymph nodes per patient) were removed. No lymph node involvement was detected in SNs with hematoxylin and eosin staining. Immunohistochemical studies identified four metastatic SNs in two patients, with micrometastases in two SNs from the first patient and isolated tumor cells in two SNs from the second patient. No false‐negative SN results were obtained.

CONCLUSIONS

The results of this study suggest that SN detection with a combination of radiocolloid and patent blue is feasible in patients with cervical carcinoma. The combination of laparoscopy and the SN procedure permitted minimally invasive management of early‐stage disease. Cancer 2003;97:3003–9. © 2003 American Cancer Society.

DOI 10.1002/cncr.11423